Literature DB >> 19759049

Further observations, mainly serological, on a cohort of women with or without pelvic inflammatory disease.

D Taylor-Robinson1, C M Stacey, J S Jensen, B J Thomas, P E Munday.   

Abstract

An analysis was undertaken of data pertaining to over 100 women with lower abdominal pain who were laparoscoped. Prior to laparoscopy, 11 of the women were considered to almost certainly have salpingitis, of whom six (55%) had salpingitis at laparoscopy; 17 to probably have salpingitis, of whom six (35%) did; 28 to possibly have salpingitis, of whom five (18%) did; and 56 to be very unlikely to have salpingitis, of whom five (9%) did. Of the 22 women who had salpingitis at laparoscopy, 14 (64%) had a Chlamydia trachomatis IgG antibody titre of >or=1:128 and might reasonably be regarded as having chlamydial disease on this basis; six without such a titre probably did not have chlamydial disease as C. trachomatis could not be detected at any genital site. At laparoscopy, 18 women had adhesions without obvious tubal inflammation; clinically, 15 of them had been regarded as possibly having salpingitis or unlikely to have it, with 12 having chronic pelvic pain. Twelve (67%) of the 18 women had a chlamydial IgG antibody titre of >or=1:128. IgM antibody was also detected most often in the 'salpingitis' group. Of 49 women without any abnormality detected at laparoscopy, nine (18%) had a high chlamydial IgG antibody titre. Overall, a woman who had a high titre of chlamydial IgG antibody and acute pelvic pain, together with a clinical picture of pelvic inflammation, was more likely to have salpingitis than adhesions alone. Likewise, a woman who had a high titre of chlamydial IgG antibody and chronic pelvic pain, together with a clinical picture suggesting that salpingitis was unlikely, was more likely to have adhesions alone than acute chlamydial salpingitis. However, while antibody measurement and seeking cervical C. trachomatis may help in formulating a diagnosis, there seems no simple way of detecting the small proportion of women who are infected by C. trachomatis in the upper genital tract but whose laparoscopic findings indicate normality. So far as patient care is concerned, the only way of preventing damage to the upper genital tract is to treat early on the basis of suspicion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759049     DOI: 10.1258/ijsa.2008.008489

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  5 in total

1.  Pelvic inflammatory disease and salpingitis: incidence of primary and repeat episodes in England.

Authors:  M J Price; A E Ades; N J Welton; I Simms; P J Horner
Journal:  Epidemiol Infect       Date:  2016-09-28       Impact factor: 4.434

2.  Management of Chlamydia trachomatis genital tract infection: screening and treatment challenges.

Authors:  Brandie D Taylor; Catherine L Haggerty
Journal:  Infect Drug Resist       Date:  2011-01-20       Impact factor: 4.003

3.  High Plasmid Gene Protein 3 (Pgp3) Chlamydia trachomatis Seropositivity, Pelvic Inflammatory Disease, and Infertility Among Women, National Health and Nutrition Examination Survey, United States, 2013-2016.

Authors:  Gloria E Anyalechi; Jaeyoung Hong; Damien C Danavall; Diana L Martin; Sarah E Gwyn; Patrick J Horner; Brian H Raphael; Robert D Kirkcaldy; Ellen N Kersh; Kyle T Bernstein
Journal:  Clin Infect Dis       Date:  2021-10-20       Impact factor: 20.999

4.  Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model.

Authors:  Malcolm J Price; A E Ades; Daniela De Angelis; Nicky J Welton; John Macleod; Kate Soldan; Ian Simms; Katy Turner; Paddy J Horner
Journal:  Am J Epidemiol       Date:  2013-06-27       Impact factor: 4.897

5.  Proportion of Pelvic Inflammatory Disease Cases Caused by Chlamydia trachomatis: Consistent Picture From Different Methods.

Authors:  Malcolm J Price; A E Ades; Nicky J Welton; Ian Simms; John Macleod; Paddy J Horner
Journal:  J Infect Dis       Date:  2016-06-03       Impact factor: 5.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.